

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **RAPID DOSE THERAPEUTICS CORP** (the "Issuer").

Trading Symbol: **DOSE**

Number of Outstanding Listed Securities: 117,808,298 Common Shares

Date **February 29 2024**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company continues to focus on execution of its business strategy to provide proprietary oral thin film delivery technologies designed to improve patient outcomes.

The Company closed on \$1,100,000 in a first tranche of its previously announced equity private placement financing (the “Financing”) which contemplated up to \$7,000,000 of gross proceeds, consisting of up to 41,176,470 units (the “Units”) at a price of \$0.17 per Unit. On February 16, 2024 the first tranche of the Financing closed with 6,470,588 Units purchased; and accordingly, the Company issued 6,470,588 Common Shares and 6,470,588 Warrants. On February 23, 2024 the second tranche of the Financing closed. A total of 1,176,470 Units were purchased and accordingly, the Company issued a further 1,176,470 Common Shares and 1,176,470 Warrants.

2. Provide a general overview and discussion of the activities of management.

The Company’s management continues to execute on its business strategy focusing on executing its fiscal year 2025 business plan commencing March 1, 2024. The Company is continuing to raise capital through its private placement offering, with the offering expiry date extended to April 14, 2024.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Cannabis contracts?

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the

disposition was to a Related Person of the Issuer and provide details of the relationship.

N/A

8. Describe the acquisition of new customers or loss of customers.

N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

N/A

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No change in the month of February 2024

14. Provide details of any changes in directors, officers or committee members.

15. No change in the month of February 2024

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Company has licensees in the cannabis business which involves certain risks and uncertainties that may have impact on the Company. Please refer to the "Risk Factors" section of the Listing Statement dated January 29, 2024, which is available on SEDAR at www.sedar.com.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there was no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated **March 6 2024**

Name of Director or Senior Officer

Signed "Mark Upsdell"

Signature

Chief Executive Officer

Official Capacity

Issuer Details		
Name of Issuer RAPID DOSE THERAPEUTICS CORP.	For Month End February 2024	Date of Report YY/MM/D 24/03//06
Issuer Address 1121 Walkers Line, Unit 3A		
City/Province/Postal Code Burlington, Ontario	Issuer Fax No. (416) 361-1333	Issuer Telephone No. (416) 477-1052
Contact Name Mark Upsdell	Contact Position CEO	Contact Telephone No. (647) 200-4709
Contact Email Address mupsdell@rapid-dose.com	Web Site Address www.rapid-dose.com	